Global Knee Denervation Market Growth 2025-2031
Description
The global Knee Denervation market size is predicted to grow from US$ 404 million in 2025 to US$ 1273 million in 2031; it is expected to grow at a CAGR of 21.1% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Knee denervation is a minimally invasive medical procedure designed to reduce chronic knee pain, typically in patients with osteoarthritis or persistent pain following knee surgeries, such as knee replacements. The procedure involves selectively interrupting the sensory nerves that transmit pain signals from the knee to the brain. This is achieved without affecting motor function, thereby preserving joint movement.
Osteoarthritis (OA) is a degenerative disease common in synovial joints, which can cause degeneration of articular cartilage, bone hyperplasia at the joint margin and under the cartilage, etc. Knee osteoarthritis (KOA) is the most common knee disease in the limb joints. Domestic statistics show that more than 3% of people in my country suffer from OA, and KOA accounts for the majority. As my country gradually enters an aging society, the incidence of KOA is higher in the population. According to relevant data, the incidence rate in people over 60 years old is as high as 12%, and it is increasing with age.
KOA is essentially a degenerative disease and cannot be cured clinically. At present, KOA patients mostly use conservative treatments such as physical therapy, analgesics and intra-articular injections to control pain and improve their quality of life. Before drug intervention, there are auxiliary treatment measures such as physical therapy, exercise, and weight loss. It is generally believed that anti-inflammatory analgesics are the first choice for the treatment of KOA, but long-term use often produces adverse reactions. Intra-articular injection of glucocorticoids or sodium hyaluronate is believed to relieve inflammation in the joint and promote cartilage repair. Repeated injections can maintain the efficacy, but the effect will still decline after several years. Total knee arthroplasty (TKA) surgery is considered to be the only effective ultimate solution, but some patients still have poor postoperative effects or long-term postoperative pain. The urgent need for pain treatment in KOA patients has given rise to the application of Knee Denervation technology in this field.
Knee Denervation includes traditional radiofrequency ablation (RFA), pulsed radiofrequency (PRF), cooled RFA (CRF) and laser treatment. The principles, parameters and efficacy of Knee Denervation technology are still in the early stages, which leads to large differences in the technical methods used by different research teams. However, through a systematic evaluation of numerous clinical trials and case reports, it can still be concluded that Knee Denervation can relieve pain and improve quality of life for up to about 1 year in the treatment of postoperative pain after KOA or TKA, and has the advantages of less trauma and fewer complications.
According to our data, the global volume of Knee Denervation surgeries will be around 130,000 in 2024, and the volume is expected to reach 155,000 in 2025. The compound annual growth rate of Knee Denervation will reach more than 15% in the next five years, and the market size will exceed US$100 million by 2030. From a regional perspective, North America occupies a major position in the Knee Denervation industry with its complete medical facilities and advanced technology, with a market share of nearly 50% in 2024, followed by Europe and Asia Pacific. From a technical point of view, the main method of Knee Denervation is radiofrequency ablation, which will account for more than 90% in 2024, but laser therapy (invasive LA) and other methods are gradually showing their advantages and are developing rapidly.
With the extension of life expectancy, the health problems caused by degenerative diseases will inevitably become a major health threat. The knee joint is an important load-bearing joint in the human body. Chronic pain, especially KOA, will seriously reduce the quality of life of patients. Patients with moderate to severe or refractory KOA benefit less from traditional treatments and have to endure many adverse reactions. TKA surgery can only solve the problems of some patients. Some patients still have poor surgical results or do not have the conditions for surgical treatment. Knee Denervation for pain treatment has shown good therapeutic effects and high safety, and has huge market potential in the future.
LP Information, Inc. (LPI) ' newest research report, the “Knee Denervation Industry Forecast” looks at past sales and reviews total world Knee Denervation sales in 2024, providing a comprehensive analysis by region and market sector of projected Knee Denervation sales for 2025 through 2031. With Knee Denervation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Knee Denervation industry.
This Insight Report provides a comprehensive analysis of the global Knee Denervation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Knee Denervation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Knee Denervation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Knee Denervation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Knee Denervation.
This report presents a comprehensive overview, market shares, and growth opportunities of Knee Denervation market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Standard RFA
Cooled RFA
Others
Segmentation by Application:
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Boston Scientific
Stryker
Abbott
Avanos Medical (coolief)
Cosman Medical
Diros Technology
Vantage MedTech
STARmed America
Beijing Neo Science
Key Questions Addressed in this Report
What is the 10-year outlook for the global Knee Denervation market?
What factors are driving Knee Denervation market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Knee Denervation market opportunities vary by end market size?
How does Knee Denervation break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Knee denervation is a minimally invasive medical procedure designed to reduce chronic knee pain, typically in patients with osteoarthritis or persistent pain following knee surgeries, such as knee replacements. The procedure involves selectively interrupting the sensory nerves that transmit pain signals from the knee to the brain. This is achieved without affecting motor function, thereby preserving joint movement.
Osteoarthritis (OA) is a degenerative disease common in synovial joints, which can cause degeneration of articular cartilage, bone hyperplasia at the joint margin and under the cartilage, etc. Knee osteoarthritis (KOA) is the most common knee disease in the limb joints. Domestic statistics show that more than 3% of people in my country suffer from OA, and KOA accounts for the majority. As my country gradually enters an aging society, the incidence of KOA is higher in the population. According to relevant data, the incidence rate in people over 60 years old is as high as 12%, and it is increasing with age.
KOA is essentially a degenerative disease and cannot be cured clinically. At present, KOA patients mostly use conservative treatments such as physical therapy, analgesics and intra-articular injections to control pain and improve their quality of life. Before drug intervention, there are auxiliary treatment measures such as physical therapy, exercise, and weight loss. It is generally believed that anti-inflammatory analgesics are the first choice for the treatment of KOA, but long-term use often produces adverse reactions. Intra-articular injection of glucocorticoids or sodium hyaluronate is believed to relieve inflammation in the joint and promote cartilage repair. Repeated injections can maintain the efficacy, but the effect will still decline after several years. Total knee arthroplasty (TKA) surgery is considered to be the only effective ultimate solution, but some patients still have poor postoperative effects or long-term postoperative pain. The urgent need for pain treatment in KOA patients has given rise to the application of Knee Denervation technology in this field.
Knee Denervation includes traditional radiofrequency ablation (RFA), pulsed radiofrequency (PRF), cooled RFA (CRF) and laser treatment. The principles, parameters and efficacy of Knee Denervation technology are still in the early stages, which leads to large differences in the technical methods used by different research teams. However, through a systematic evaluation of numerous clinical trials and case reports, it can still be concluded that Knee Denervation can relieve pain and improve quality of life for up to about 1 year in the treatment of postoperative pain after KOA or TKA, and has the advantages of less trauma and fewer complications.
According to our data, the global volume of Knee Denervation surgeries will be around 130,000 in 2024, and the volume is expected to reach 155,000 in 2025. The compound annual growth rate of Knee Denervation will reach more than 15% in the next five years, and the market size will exceed US$100 million by 2030. From a regional perspective, North America occupies a major position in the Knee Denervation industry with its complete medical facilities and advanced technology, with a market share of nearly 50% in 2024, followed by Europe and Asia Pacific. From a technical point of view, the main method of Knee Denervation is radiofrequency ablation, which will account for more than 90% in 2024, but laser therapy (invasive LA) and other methods are gradually showing their advantages and are developing rapidly.
With the extension of life expectancy, the health problems caused by degenerative diseases will inevitably become a major health threat. The knee joint is an important load-bearing joint in the human body. Chronic pain, especially KOA, will seriously reduce the quality of life of patients. Patients with moderate to severe or refractory KOA benefit less from traditional treatments and have to endure many adverse reactions. TKA surgery can only solve the problems of some patients. Some patients still have poor surgical results or do not have the conditions for surgical treatment. Knee Denervation for pain treatment has shown good therapeutic effects and high safety, and has huge market potential in the future.
LP Information, Inc. (LPI) ' newest research report, the “Knee Denervation Industry Forecast” looks at past sales and reviews total world Knee Denervation sales in 2024, providing a comprehensive analysis by region and market sector of projected Knee Denervation sales for 2025 through 2031. With Knee Denervation sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Knee Denervation industry.
This Insight Report provides a comprehensive analysis of the global Knee Denervation landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Knee Denervation portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Knee Denervation market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Knee Denervation and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Knee Denervation.
This report presents a comprehensive overview, market shares, and growth opportunities of Knee Denervation market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Standard RFA
Cooled RFA
Others
Segmentation by Application:
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Boston Scientific
Stryker
Abbott
Avanos Medical (coolief)
Cosman Medical
Diros Technology
Vantage MedTech
STARmed America
Beijing Neo Science
Key Questions Addressed in this Report
What is the 10-year outlook for the global Knee Denervation market?
What factors are driving Knee Denervation market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Knee Denervation market opportunities vary by end market size?
How does Knee Denervation break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
103 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Knee Denervation by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Knee Denervation by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
